Literature DB >> 25057866

Surgical management of high-grade glioma: a standard of care.

Colin Watts1.   

Abstract

Neurosurgical oncology for intrinsic glioma is evolving rapidly. It must be patient-centered, consultant-led and research-orientated. The value of specialist neurosurgical engagement is becoming more widely recognized. Detailed evaluation tailored to each patient is essential before the surgical admission, in conjunction with clinical oncology input. Medical optimization, collation of magnetic resonance datasets for preoperative planning and providing an informed explanation of the proposed management and its alternatives are all part of the neurosurgeon's remit. Meticulous microsurgical technique during surgery utilizing modern neuronavigation and physiological monitoring are integral components of the specialist armamentarium. A clear understanding of the rationale for surgical intervention, including its place alongside radiotherapy and chemotherapy, informs surgical decision-making. Recognition and understanding of these issues are driving the evolution of neurosurgical management of high-grade glioma. New challenges are emerging and need to be critically evaluated in robustly designed clinical trials.

Entities:  

Mesh:

Year:  2012        PMID: 25057866      PMCID: PMC6178118          DOI: 10.2217/cns.12.26

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  86 in total

1.  Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy.

Authors:  Ellen S Mandl; C M F Dirven; D R Buis; T J Postma; W P Vandertop
Journal:  Surg Neurol       Date:  2008-02-08

2.  Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance.

Authors:  Daniela Kuhnt; Andreas Becker; Oliver Ganslandt; Miriam Bauer; Michael Buchfelder; Christopher Nimsky
Journal:  Neuro Oncol       Date:  2011-09-12       Impact factor: 12.300

3.  Predictive value of inferior fronto-occipital fasciculus (IFO) DTI-fiber tracking for determining the extent of resection for surgery of frontal and temporal gliomas preoperatively.

Authors:  G Bertani; G Carrabba; F Raneri; E Fava; A Castellano; A Falini; A Casarotti; S M Gaini; L Bello
Journal:  J Neurosurg Sci       Date:  2012-06       Impact factor: 2.279

4.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

5.  Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study.

Authors:  Arya Nabavi; Holger Thurm; Basilios Zountsas; Thorsten Pietsch; Heinrich Lanfermann; Uwe Pichlmeier; Maximilian Mehdorn
Journal:  Neurosurgery       Date:  2009-12       Impact factor: 4.654

6.  Age as a predictive factor in glioblastomas: population-based study.

Authors:  Daisuke Kita; Ilja F Ciernik; Salvatore Vaccarella; Silvia Franceschi; Paul Kleihues; Urs M Lütolf; Hiroko Ohgaki
Journal:  Neuroepidemiology       Date:  2009-03-27       Impact factor: 3.282

7.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

8.  Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme.

Authors:  Matthew J McGirt; Debraj Mukherjee; Kaisorn L Chaichana; Khoi D Than; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

9.  A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.

Authors:  Lula Rosso; Cathryn S Brock; James M Gallo; Azeem Saleem; Patricia M Price; Federico E Turkheimer; Eric O Aboagye
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

10.  Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds.

Authors:  N G Burnet; S J Jefferies; R J Benson; D P Hunt; F P Treasure
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.